Antibody‑drug conjugates (ADCs) remain an area of extreme focus in the pharmaceuticals space, with the market projected to hit a $40bn valuation by 2040. However, technical hurdles in the field remain ...

As we head into the new year, now is the time to look back on the activity seen in the pharma space in 2025 and consider what it can tell us about the market’s development in 2026. This month’s cover ...